Preliminary data on effects of metformin on PED/PEA-15 cellular levels in obese women with polycystic ovary syndrome

Journal of Endocrinological Investigation

Volumn 33, Issue 7, 2010, Pages 446-450

  Savastano, S ^a   Valentino, R ^b   Pizza, G ^a   De Rosa, A ^a   Orio, F ^b   Passaretti, F ^a   Formisano, P ^a   Lombardi, G ^a   Beguinot, F ^a   Colao, A ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF NAPLES PARTHENOPE   (Italy)

Author keywords

Metformin; Obesity; PCOS; PED PEA 15

Indexed keywords

ANDROGEN; GLUCOSE; INSULIN; METFORMIN; PEA 15 PROTEIN; PED PROTEIN; PHOSPHOPROTEIN; SCAFFOLD PROTEIN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; UNCLASSIFIED DRUG;

ADULT; ANDROGEN BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC OBESITY; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; HYPERANDROGENISM; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LOW DRUG DOSE; OBESITY; OUTCOME ASSESSMENT; OVARY POLYCYSTIC DISEASE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TESTOSTERONE BLOOD LEVEL;

EID: 77957289193     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.1007/BF03346622     Document Type: Article

References (22)

1. Essah PA, Nestler JE. The metabolic syndrome in policistic ovary Syndrome. J Endocrinol Invest 2006, 29: 270-80.
2. Alexander CJ, Tangchitnob EP, Lepor NE. Polycystic ovary syndrome: a major unrecognized cardiovascular risk factor in women. Rev Cardiovasc Med 2009, 10: 83-90.
3. Diamanti-Kandarakis E. Insulin resistance in PCOS. Endocrine 2006, 30: 13-7.
4. Fiory F, Formisano P, Perruolo G, Beguinot F. Frontiers: PED/PEA-15, a multifunctional protein controlling cell survival and glucose metabolism. Am J Physiol Endocrinol Metab 2009, 297: E592-601.
5. Condorelli G, Vigliotta G, Trencia A, et al. Protein kinase C (PKC)-alpha activation inhibits PKC-zeta and mediates the action of PED/PEA-15 on glucose transport in the L6 skeletal muscle cells. Diabetes 2001, 50: 1244-52.
6. Valentino R, Lupoli GA, Raciti GA, et al. The PEA15 gene is overexpressed and related to insulin resistance in healthy first-degree relatives of patients with type 2 diabetes. Diabetologie 2006, 49: 3058-66.
7. Savastano S, Orio F Jr, Palomba S, et al. Overexpression of the phosphoprotein enriched in diabetes gene product (Ped/pea-15) in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2007, 67: 557-62.
8. American Association of Clinical Endocrinologists Polycystic Ovary Syndrome Writing Committee. American Association of Clinical Endocrinologists position statement on metabolic and cardiovascular consequences of polycystic ovary syndrome. Endocr Pract 2005, 11: 126-34.
9. The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004, 19: 41-7.
10. th ed. Philadelphia: WB Saunders 1999, 562-93.
11. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961, 21: 1440-7.
12. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997, 20: 1183-97.
13. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28: 412-9.
14. Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000, 85: 2402-10. (Pubitemid 32269192)
15. Matsuda M, De Fronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing comparison with the euglycemic insulin clamp. Diabetes Care 1999, 22: 1462-70.
16. de Paula Martins W, Santana LF, Nastri CO, Ferriani FA, de Sa MF, Dos Reis RM. Agreement among insulin sensitivity indexes on the diagnosis of insulin resistance in polycystic ovary syndrome and ovulatory women. Eur J Obstet Gynecol Reprod Biol 2007, 133: 203-7.
17. Nieuwenhuis-Ruifrok AE, Kuchenbecker WK, Hoek A, Middleton P, Norman RJ. Insulin sensitizing drugs for weight loss in women of reproductive age who are overweight or obese: systematic review and meta-analysis. Hum Reprod Update 2009, 15: 57-68.
18. Bremer AA, Miller WL. The serine phosphorylation hypothesis of polycystic ovary syndrome: a unifying mechanism for hyperandro-genemia and insulin resistance. Fertil Steril 2008, 89: 1039-48.
19. Barba M, Schünemann HJ, Sperati F, et al. The effects of metformin on endogenous androgens and SHBG in women: a systematic review and meta-analysis. Clin Endocrinol (Oxf) 2009, 70: 661-70.
20. Mansfield R, Galea R, Brincat M, Hole D, Mason H. Metformin has direct effects on human ovarian steroidogenesis. Fertil Steril 2003, 79: 956-62. (Pubitemid 36385020)
21. Jakubowska J, Bohdanowicz-Pawlak A, Milewicz A, et al. Plasma cytokines in obese women with polycystic ovary syndrome, before and after metformin treatment. Gynecol Endocrinol 2008, 24: 378-84.
22. Dunaif A. Drug insight: insulin-sensitizing drugs in the treatment of polycystic ovary syndrome-a reappraisal. Nat Clin Pract Endocrinol Metab 2008, 4: 272-83. (Pubitemid 351571139)